Volume 124, Issue 3 , Pages 536-543, September 2009
Comèl-Netherton syndrome defined as primary immunodeficiency
Background
Mutations in serine protease inhibitor Kazal-type 5 (SPINK5), encoding the serine protease inhibitor lympho-epithelial Kazal-type 5 related inhibitor (LEKTI), cause Comèl-Netherton syndrome, an autosomal-recessive disease characterized by congenital ichthyosis, bamboo hair, and atopic diathesis. Despite increased frequency of infections, the immunocompetence of patients with Comèl-Netherton syndrome has not been extensively investigated.
Objective
To define Comèl-Netherton syndrome as a primary immunodeficiency disorder and to explore the benefit of intravenous immunoglobulin replacement therapy.
Methods
We enrolled 9 patients with Comèl-Netherton syndrome, sequenced SPINK5, and analyzed LEKTI expression by immunohistochemistry. Immune function was assessed by measuring cognate immunity, serum cytokine levels, and natural killer cell cytotoxicity.
Results
All patients presented with recurrent skin infections caused predominantly by Staphylococcus aureus. All but 1 reported recurrent respiratory tract infections; 78% had sepsis and/or pneumonia; 67% had recurrent gastrointestinal disease and failure to thrive. Mutations in SPINK5—including 6 novel mutations—were identified in 8 patients. LEKTI expression was decreased or absent in all patients.
Immunologic evaluation revealed reduced memory B cells and defective responses to vaccination with Pneumovax and bacteriophage phiX174, characterized by impaired antibody amplification and class-switching. Immune dysregulation was suggested by a skewed Th1 phenotype and elevated proinflammatory cytokine levels, whereas serum concentrations of the chemokine (C-C motif) ligand 5 and natural killer cell cytotoxicity were decreased. Treatment with intravenous immunoglobulin resulted in remarkable clinical improvement and temporarily increased natural killer cell cytotoxicity.
Conclusion
These data provide new insights into the immunopathology of Comèl-Netherton syndrome and demonstrate that this multisystem disorder, characterized by lack of LEKTI expression in epithelial cells, is complicated by cognate and innate immunodeficiency that responds favorably to intravenous immunoglobulin therapy.
Key words: Comèl-Netherton syndrome, SPINK5, LEKTI, immune deficiency, NK-cell cytotoxicity, selective antibody deficiency, IVIG, ichthyosis, bamboo hair, atopic diathesis
Abbreviations used: CCL5, Chemokine (C-C motif) ligand 5, FITC, Fluorescein isothiocyanate, FOXP3, Forkhead box protein 3, IVIG, Intravenous immunoglobulin, LEKTI, Lympho-epithelial Kazal-type 5 related inhibitor, NK, Natural killer, SPINK5, Serine protease inhibitor Kazal-type 5, TCRBV, T-cell receptor β-chain variable, WAS, Wiskott-Aldrich syndrome
Supported by the Fritz Thyssen Foundation (Az 10.07.1.159), the American Academy of Allergy, Asthma and Immunology's Strategic Training in Allergy Research Award 2007 (E.D.R.), National Institutes of Health grants AI-063267 (T.R.T.), AI-47040 and AI-54843 (M.I.M.), AI-067946 and AI-079731 (J.S.O.), HD-017427 (H.D.O), and the Jeffrey Modell Foundation (H.D.O. and J.S.O.).
Disclosure of potential conflict of interest: M. L. Markert receives research support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases and the US Food and Drug Administration. E. R. Stiehm has provided legal consultation services/expert witness testimony in cases related to vaccine injury and mold-associated immunodeficiencies, is on the board of directors for the Immune Deficiency Foundation and USIDnet, is on the review committee for the March of Dimes, and is an editor for Up-to-Date Web Based Information. M. P. Upton receives research support from the Department of Health and Human Services and the Robert Wood Johnson Foundation; has provided legal consultation/expert witness testimony in cases related to mucinous carcinoma of the pancreas, duodenal adenocarcinoma, papillary thyroid carcinoma, retained product of conception, and small bowel obstruction; is a CME Editor for the American Journal of Clinical Pathology; and has received honoraria from Northwestern University, the Pacific Northwest Society of Pathologies, the Twin Cities Pathology Society, Swedish Hospital—Cherry Hill Family Practice Residency, and the University of Illinois. T. R. Torgerson receives consultant fees and research support from Baxter Pharmaceuticals. J. S. Orange receives research support from the National Institutes of Health. H. D. Ochs is a speaker for the American Academy of Allergy, Asthma & Immunology; is on the advisory board for Baxter; and receives research support from the Jeffrey Modell Foundation and CSL Behring. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(09)00878-1
doi:10.1016/j.jaci.2009.06.009
© 2009 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Refers to erratum:
- Correction
Volume 124, Issue 3 , Pages 536-543, September 2009
